Data Collective (DCVC)

Tracked participation in 2 Atlas companies, with 1 explicitly attributed lead.

2portfolio companies

5round participations

1lead positions

$60Mled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Oct 2017RecursionSeries B$60M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)Recursion—Oct 2016 → Jul 20194 rounds1 led—

MMythic—Mar 2017 → Mar 20171 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Jul 15, 2019RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries C$121M—Participant

Source ↗

Oct 03, 2017RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries B$60M—Lead

Source ↗

Mar 22, 2017MMythicSeries A$9M—Participant

Source ↗

Nov 22, 2016RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries A (additional close)$2.2M—Participant

Source ↗

Oct 03, 2016RRecursionScienceRecursion (NASDAQ: RXRX) is a clinical-stage TechBio company developing an end-to-end, AI-native drug discovery and…$1.2BraisedRecent roundsPublic Offering (equity) · Jun 2024$200M · Public market investors (follow-on offering)PIPE / strategic investment (NVIDIA investment) · Jul 2023$50M · NVIDIADebt financing (credit facility / term loan) · Jan 2023$11.9M · led by Midcap Financial Trust (Midcap)RecursionSeries A$12.9M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗

Mar 22, 2017MMythicSeries A$9M—Participant

Source ↗